BIOMARIN PHARMACEUTICAL INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BMRN in the last 30 days.
See all $BMRN insider activity →BioMarin Pharmaceutical (BMRN) reported a $283M Q3 IPR&D expense, reducing GAAP and non-GAAP EPS by $1.50. Non-GAAP EPS is estimated at $1.25. The expense impacts financial results for the quarter.
BIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition Estimated Financial Impact of the Alesta Acquisition In connection with its acquisition of Alesta Therapeutics B.V. (Alesta), a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid),
BioMarin (BMRN) presented five-year data for POMBILITI + OPFOLDA in late-onset Pompe disease at the World Muscle Society Congress. The study showed durable motor function and pulmonary stabilization. No new safety signals were identified. Additionally, BioMarin shared positive Phase 1/2 data for nivudirsen (BMN 351) in Duchenne muscular dystrophy, showing favorable tolerability and positive dystrophin expression.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning BMRN (BIOMARIN PHARMACEUTICAL INC). Coverage has skewed bearish: 1 bullish, 0 neutral, and 4 bearish.
Recent BMRN coverage spans corporate actions, earnings and market movers.
The large one‑time expense will likely depress the stock as earnings guidance is reduced.
The disclosed acquisition charges reduce earnings expectations, likely prompting a sell‑off.
Positive long-term data should support the drug's market perception and may lift the stock.
Layoffs suggest cost‑cutting but may signal weaker demand, likely pressuring the stock lower.
The agreement creates a new royalty stream for BioMarin and resolves pending litigation, which could be viewed positively by investors.
AlphAI scores every news story that mentions BMRN with an AI model for sentiment and relevance, and aggregates insider trades from BIOMARIN PHARMACEUTICAL INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
BioMarin Pharmaceutical (BMRN) reported a $283M Q3 IPR&D expense, reducing GAAP and non-GAAP EPS by $1.50. Non-GAAP EPS is estimated at $1.25. The expense impacts financial results for the quarter.
1 min readBIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition Estimated Financial Impact of the Alesta Acquisition In connection with its acquisition of Alesta Therapeutics B.V. (Alesta), a Dutch private limited liability company (besloten vennootschap met beperkte aansprakelijkheid),
2 min readBioMarin (BMRN) presented five-year data for POMBILITI + OPFOLDA in late-onset Pompe disease at the World Muscle Society Congress. The study showed durable motor function and pulmonary stabilization. No new safety signals were identified. Additionally, BioMarin shared positive Phase 1/2 data for nivudirsen (BMN 351) in Duchenne muscular dystrophy, showing favorable tolerability and positive dystrophin expression.
2 min readBioMarin Pharmaceuticals will lay off 119 employees, mostly in Novato, by December to consolidate operations. The cuts follow previous layoffs and acquisitions, including a $4.8 billion deal for Amicus Therapeutics. Q2 revenue rose 20% to $990 million, but net income fell 81% to $45 million. The company plans to spend $92 million on restructuring by 2027.
2 min readBIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, BioMarin Pharmaceutical Inc. (BioMarin) entered into a Settlement and License Agreement (the Agreement) with Ascendis Pharma A/S (Ascendis). The terms of the Agreement are consistent with those contained
1 min readAscendis Pharma (ASND) and BioMarin (BMRN) settled a patent dispute, with ASND paying BMRN royalties on Yuviwel sales. ASND rose 6% and BMRN 1%. Analysts adjusted targets but kept ratings unchanged, citing legal clarity and growth prospects.
2 min readBioMarin (BMRN) expects $200M in cost savings from its Amicus acquisition, with most synergies realized by 2027. The company anticipates VOXZOGO to hit $1B in revenue this year, its first blockbuster product. BioMarin also plans to advance deleveraging and pursue further transactions, with a $5B deal capacity restored by mid-2027.
3 min readBioMarin Pharmaceutical reported positive Phase 3 trial data for VOXZOGO in treating hypochondroplasia, supporting an FDA application. The data may expand VOXZOGO's market and impact BioMarin's growth strategy. Analysts project revenue of $5.0B and earnings of $1.3B by 2029, with a potential 41% upside. Risks include pricing pressure, competition, and high R&D costs.
3 min readBioMarin Pharmaceutical (BMRN) saw significant bullish options activity, with a 182:1 call-to-put ratio. A large call spread bet targets $100 by April 2027, indicating confidence in a 37% upside. Recent earnings beats and pipeline developments support this outlook, though competitive risks remain. Technical indicators also suggest strong momentum.
2 min readBIOMARIN PHARMACEUTICAL INC (BMRN) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 15, 2026, BioMarin Pharmaceutical Inc. (BioMarin) announced its decision to discontinue development of VOXZOGO for children with Noonan syndrome. BioMarin made this decision after assessing a number of factors, including the feasibility of the
1 min read
